Bio-Techne Corp (TECH)

Currency in USD
47.41
-9.28(-16.36%)
Closed·
47.50+0.10(+0.20%)
·
Earnings results expected today
Unusual trading volume
Trading near 52-week Low
TECH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
45.1256.68
52 wk Range
45.1272.16
Key Statistics
Prev. Close
56.68
Open
56.68
Day's Range
45.12-56.68
52 wk Range
45.12-72.16
Volume
11.94M
Average Volume (3m)
2.39M
1-Year Change
0.5448%
Book Value / Share
12.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TECH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
72.27
Upside
+52.44%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Bio-Techne Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

10 Buy
4 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 72.27
(+52.44% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Evercore ISI
Hold54.00+13.90%68.00MaintainApr 06, 2026
TD Cowen
Buy80.00+68.74%-MaintainMar 17, 2026
Argus
Buy68.00+43.43%65.00MaintainMar 12, 2026
Wells Fargo
Buy76.00+60.30%70.00MaintainFeb 06, 2026
UBS
Buy79.00+66.63%70.00MaintainFeb 05, 2026

Bio-Techne Corp Earnings Call Summary for Q3/2026

  • Bio-Techne Q3 FY2026 revenue fell 2% YoY to $311.4M, missing estimates of $316.12M; adjusted EPS of $0.53 missed forecast of $0.54.
  • Stock plummeted 13.42% in pre-market trading to $57 following earnings miss, reflecting significant investor disappointment with results.
  • Adjusted gross margin compressed 110 basis points YoY to 70.4%; operating cash flow remained robust at $86.7M despite revenue headwinds.
  • Company faces ongoing challenges from weak biotech funding environment and timing impacts from large OEM orders affecting quarterly performance.
  • Management projects Q4 FY2026 EPS of $0.56 with modest revenue growth; maintains focus on disciplined profitability and strategic investments.
Last Updated: 2026-05-06, 11:44 a/m
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
0.53 / 0.54
Revenue / Forecast
311.4M / 316.12M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.52%
Dividend Yield
0.58%
Industry Median 0.88%
Annualized payout
0.32
Paid quarterly
5-Years Growth
-
Growth Streak

TECH Income Statement

Compare TECH to Peers and Sector

Metrics to compare
TECH
Peers
Sector
Relationship
P/E Ratio
109.4x20.1x−0.5x
PEG Ratio
−2.330.040.00
Price/Book
4.4x2.1x2.6x
Price / LTM Sales
7.3x3.4x3.2x
Upside (Analyst Target)
32.3%38.4%47.8%
Fair Value Upside
Unlock25.2%5.9%Unlock

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
97.23M62.14%5.51B
Other Institutional Investors
78.35M37.86%4.44B
Public Companies & Retail Investors
0.000.00%0.00
Total
175.58M100.00%9.95B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.11.38%17,810,8781,009,521
BlackRock, Inc.7.75%12,129,092687,477

People Also Watch

130.30
MAA
+0.11%
1,327.04
MTD
+1.89%
61.10
COO
-0.24%
54.19
ROL
+0.15%
72.44
HSIC
-2.60%

FAQ

What Is the Bio-Techne (TECH) Stock Price Today?

The Bio-Techne stock price today is 47.41 USD.

What Stock Exchange Does Bio-Techne Trade On?

Bio-Techne is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Bio-Techne?

The stock symbol for Bio-Techne is "TECH."

Does Bio-Techne Pay Dividends? What’s The Current Dividend Yield?

The Bio-Techne dividend yield is 0.68%.

What Is the Bio-Techne Market Cap?

As of today, Bio-Techne market cap is 7.35B USD.

What Is Bio-Techne's Earnings Per Share (TTM)?

The Bio-Techne EPS (TTM) is 0.52.

When Is the Next Bio-Techne Earnings Date?

Bio-Techne will release its next earnings report on May 06, 2026.

From a Technical Analysis Perspective, Is TECH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Bio-Techne Stock Split?

Bio-Techne has split 3 times.

How Many Employees Does Bio-Techne Have?

Bio-Techne has 3100 employees.

What is the current trading status of Bio-Techne (TECH)?

As of May 06, 2026, Bio-Techne (TECH) is trading at a price of 47.41 USD, with a previous close of 56.68 USD. The stock has fluctuated within a day range of 45.12 USD to 56.68 USD, while its 52-week range spans from 45.12 USD to 72.16 USD.

What Is Bio-Techne (TECH) Price Target According to Analysts?

The average 12-month price target for Bio-Techne is 72.27 USD, with a high estimate of 80 USD and a low estimate of 54 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +52.44% Upside potential.

What Is the TECH Premarket Price?

TECH's last pre-market stock price is 57.00 USD. The pre-market share volume is 50.00, and the stock has decreased by 0.32, or 0.56%.

What Is the TECH After Hours Price?

TECH's last after hours stock price is 47.50 USD, the stock has decreased by 0.10, or 0.20%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.